AbCellera Biologics Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AbCellera Biologics Inc. (ABCL) on November 24, 2025. The report addresses a change in the Company's independent registered public accounting firm.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on governance and audit firm changes rather than financial performance data.
Material Changes
- Dismissal of Previous Auditor: The Audit Committee approved the dismissal of KPMG LLP as the independent registered public accounting firm, effective after the completion of the audit for the fiscal year ending December 31, 2025, and the subsequent filing of the Form 10-K.
- Engagement of New Auditor: The Audit Committee selected Ernst & Young LLP (EY) as the new independent registered public accounting firm for the fiscal year ending December 31, 2026, subject to standard acceptance procedures.
- Reason for Change: The dismissal of KPMG was not related to any disagreements on accounting principles, financial statement disclosure, or auditing scope. The change resulted from a formal audit firm tender process initiated earlier in the year.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The Company confirmed there were no reportable events or disagreements with KPMG during the fiscal years ended December 31, 2024 and 2023, or the subsequent interim period. KPMG's audit reports for 2023 and 2024 were unqualified and did not contain adverse opinions or disclaimers.
Key Facts for Investor Verification
- Verify the effective date of the transition from KPMG to EY, which is contingent upon the completion of the 2025 fiscal year audit and 10-K filing.
- Review the letter from KPMG LLP (Exhibit 16.1) to confirm their agreement with the Company's statements regarding the dismissal.
- Monitor the upcoming Form 10-K for the fiscal year ended December 31, 2025, for the first financial statements audited by KPMG under this transition period.
- Confirm the execution of the engagement letter with EY for the 2026 fiscal year.